

RECEIVED
FEB 20 2002
TECH CENTER 1600/2900

#2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 09/939,962
Conf. No.: 6989
Filed: August 27, 2001
Applicant: Michael B. Foster
Title: **METHOD OF OPTIMIZING GROWTH
HORMONE REPLACEMENT**
Art Unit: 1653
Examiner: Not yet assigned

RECEIVED
TECH CENTER 1600/2900
02 FEB 19 PM 12:23

Cincinnati, Ohio 45202

February 19, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56 and means of complying therewith according to 37 C.F.R. §§1.97 and 1.98, the references listed on the attached Form PTO-1449 are called to the attention of the Examiner in connection with the above-identified patent application. Copies of the cited references have already been supplied in connection with U.S. Patent Application Serial No. 09/838,968, filed April 20, 2001. The present application is a Continuation-In-Part application of 09/838,968 and claims the benefit thereof under 35 U.S.C. § 120. Therefore, under 37 C.F.R. § 1.98(d) copies of the cited references need not be provided herewith. If additional copies of these references are desired, please contact the undersigned and they will be forwarded


immediately. A copy of the art listed as 'L.T' on the attached PTO-1449 form is enclosed, as it was not previously cited in Application No. 09/838,968. No representation is made that the cited art is the only art or that the cited art represents the best art.

The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicant does not believe that any fees are due in connection with this submission. However, if such petition is due or any fees are necessary, the Commissioner may consider this to be a request for such and charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

A handwritten signature in cursive script, reading "Beverly A. Lyman", written over a horizontal line.

Beverly A. Lyman
Reg. No. 41,961

2700 Carew Tower
Cincinnati OH 45202
(513) 241-2324
(513) 421-7269 Facsimile

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
RENAS/04SERIAL NO.
09/939,962INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Michael B. FosterFILING DATE
August 27, 2001

(Use several sheets if necessary)

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	PUBLICATION DATE IF APPROPRIATE
	A.A	5	8	5	5	9	2	0	01/1999	Chien			
	A.B												
	A.C												
	A.D												
	A.E												
	A.F												
	A.G												
	A.H												
	A.I												
	A.J												
	A.K												

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Scientific program and abstracts, <u>Consultants Conference on Adult Growth Hormone Deficiency</u> , Genentech, Inc., San Francisco, CA, 1998, 6-50.
A.S	Amato et al., <u>Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 6, 1993, 1671-1676.
A.T	Andrews, <u>Forever young</u> , Smart Money, 2000, 127-132.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04	SERIAL NO. 09/939,962		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	Attanasio et al., <u>Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 1, 1997, 82-88.					
	B.S	Bates et al., <u>The effect of hypopituitarism on life expectancy</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 81, No. 3, 1996, 1169-1172.					
	B.T	Bengtsson, <u>Efficacy of growth hormone-replacement therapy: quality of life and performance</u> , The Endocrinologist, Vol. 8, No. 6, Suppl, Lippincott Williams & Wilkins, 1998, 31S-35S.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04		SERIAL NO. 09/939,962	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001		GROUP 1653	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	C.R	Bengtsson et al., <u>Treatment of adults with growth hormone (GH) deficiency with recombinant human GH</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 76, No. 2, 1993, 309-317.					
	C.S	Bengtsson, <u>The consequences of growth hormone deficiency in adults</u> , Acta Endocrinologica, Vol. 128, Supp 2, 1993, 2-5.					
	C.T	Billir, <u>Efficacy of growth hormone-replacement therapy: body composition and bone density</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1998, 15S-21S.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04		SERIAL NO. 09/939,962	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001		GROUP 1653	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	D.R	Blethen, <u>Dosing, monitoring, and safety of growth hormone-replacement therapy in adults with growth hormone deficiency</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1998, 36S-40S.					
	D.S	Brody, <u>Restoring ebbing hormones may slow aging</u> , The New York Times, July 18, 1995, late edition, Sec. C, Page 1, Col. 1, 2-10.					
	D.T	Carter, <u>Effect of anabolic hormones and insulin-like growth factor-I on muscle mass and strength in elderly persons</u> , Clinics in Geriatric Medicine, Vol. 11, No. 4, 1995, 735-748.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04	SERIAL NO. 09/939,962		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001	GROUP 1653		
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A.						
	E.B.						
	E.C.						
	E.D.						
	E.E.						
	E.F.						
	E.G.						
	E.H.						
	E.I.						
	E.J.						
	E.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L.						
	E.M.						
	E.N.						
	E.O.						
	E.P.						
	E.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	E.R.	Cuneo, <u>Efficacy of growth hormone-replacement therapy: lipid and cardiovascular effects.</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1995, 22S-30S.					
	E.S.	Cuneo et al., <u>Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency</u> , Metabolism, Vol. 42, No. 12, 1993, 1519-1523.					
	E.T.	de Boer et al., <u>Serum lipid levels in growth hormone-deficient men</u> , Metabolism, Vol. 43, No. 2, 1994, 199-203.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04	SERIAL NO. 09/939,962		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001	GROUP 1653		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A						
	F.B						
	F.C						
	F.D						
	F.E						
	F.F						
	F.G						
	F.H						
	F.I						
	F.J						
	F.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	F.R	Eden et al., <u>Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations</u> , Arteriosclerosis and Thrombosis, Vol. 13, No. 2, 1993, 296-301.					
	F.S	Ho and Hoffman, <u>Aging and Growth Hormone</u> , Horm Res, Vol. 40, 1993, 80-86.					
	F.T	Hoffman et al., <u>Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 80, No. 1, 1995, 72-77.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04		SERIAL NO. 09/939,962	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001		GROUP 1653	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A						
	G.B						
	G.C						
	G.D						
	G.E						
	G.F						
	G.G						
	G.H						
	G.I						
	G.J						
	G.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L						
	G.M						
	G.N						
	G.O						
	G.P						
	G.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	G.R	Holloway et al., <u>Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women</u> , Journal of Clinical Endocrinology and Metabolism, 1994, 470-479.					
	G.S	Johansson et al., <u>Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters</u> , Neuroendocrinology, Vol. 61, 1995, 57-66.					
	G.T	Kirkland et al., <u>Physician and clinic charges for diagnosing growth hormone deficiency</u> , J. Pediatrics, 1996, S61-S62.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04	SERIAL NO. 09/939,962		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001	GROUP 1653		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	H.R	Kleinberg and Melmed, <u>The adult growth hormone deficiency syndrome: signs, symptoms, and diagnosis</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1998, 8S-14S.					
	H.S	Lieberman and Hoffman, <u>Growth hormone deficiency in adults: characteristics and response to growth hormone replacement</u> , J. Pediatrics, Vol. 128, No. 5, Part 2, 1996, S58-S60.					
	H.T	Meling and Nylen, <u>Growth hormone deficiency in adults: a review</u> , The American Journal of the Medical Sciences, Vol. 311, No. 4, 1996, 153-166.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04	SERIAL NO. 09/939,962		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001	GROUP 1653		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	I.L						
	I.M						
	I.N						
	I.O						
	I.P						
	I.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	I.R	Drake and Monson, <u>Individual susceptibility and GH dosing regimen in adults in Growth Hormone Therapy</u> , John P. Monson, Ed., Blackwell Science Ltd., Osney Mead, Oxford, 1999.					
	I.S	Nass et al., <u>Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 80, No. 2, 1995, 552-557.					
	I.T	Rosen et al., <u>Decreased psychological well-being in adult patients with growth hormone deficiency</u> , Clinical Endocrinology, Vol. 40, 1994, 111-116.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04		SERIAL NO. 09/939,962	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001		GROUP 1653	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	J.R	Rosen et al., <u>Cardiovascular risk factors in adult patients with growth hormone deficiency</u> , Acta Endocrinologica, Vol. 129, 1993, 195-200.					
	J.S	Rosen and Bengtsson, <u>Premature mortality due to cardiovascular disease in hypopituitarism</u> , The Lancet, Vol. 336, 1990, 285-288.					
	J.T	Rudman, M.D. et al., <u>Effects of human growth hormone in men over 60 years old</u> , The New England Journal of Medicine, Vol. 323, No. 1, 1990, 1-6.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/04	SERIAL NO. 09/939,962		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Michael B. Foster			
				FILING DATE August 27, 2001		GROUP 1653	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A						
	K.B						
	K.C						
	K.D						
	K.E						
	K.F						
	K.G						
	K.H						
	K.I						
	K.J						
	K.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L						
	K.M						
	K.N						
	K.O						
	K.P						
	K.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	K.R	Russell-Jones et al., <u>The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients</u> , Clinical Endocrinology, Vol. 41, 1994, 345-350.					
	K.S	Salomon et al., <u>The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency</u> , The New England Journal of Medicine, Vol. 321, No. 26, 1989, 1797-1803.					
	K.T	Schwartz, <u>Tropic factor supplementation: effect on the age-associated changes in body composition</u> , The Journal of Gerontology, Series A, Vol. 50A, 1995, 151-156.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
RENAS/04SERIAL NO.
09/939,962INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Michael B. FosterFILING DATE
August 27, 2001GROUP
1653

(37 CFR 1.98(b))

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	L.A.						
	L.B.						
	L.C.						
	L.D.						
	L.E.						
	L.F.						
	L.G.						
	L.H.						
	L.I.						
	L.J.						
	L.K.						

RECEIVED
FEB 20 2002
TECH CENTER 1600/2900

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	L.L.						
	L.M.						
	L.N.						
	L.O.						
	L.P.						
	L.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	L.R.	Shore et al., <u>Bone mineral status in growth hormone deficiency</u> J. Pediatrics, Vol. 96, No. 3, part 1, 1980, 393-396.
	L.S.	Sönksen and Weissberger, <u>Growth hormone deficiency in adults</u> Growth Genetics and Hormones, Vol. 14, No. 3, 1998, 41-48.
	L.T.	<u>Fundamentals of Clinical Chemistry</u> , Norbert W. Tietz, Ph.D., Ed., W.B. Saunders Co., Philadelphia, 1987, 965.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.